What the business is, and whether it's a good one at a fair price.
Manufactures and sells specialty chemicals and pharmaceutical products from GMP-certified facilities at Palghar and Hyderabad. The product range covers pharmaceuticals, active pharmaceutical ingredients (APIs), drugs, chemicals, and healthcare products. Growth has come through acquisitions, including Ratna Lifesciences and a 51% stake in Ishwari Healthcare, and through export expansion, supported by a wholly-owned US subsidiary called Sudarshan Industries Inc. incorporated in Delaware. FY26 revenue was ₹703.0565 crore (up from ₹505 crore in FY25), with net profit of ₹23.3717 crore and an EBITDA margin of 8.5382%. Export turnover for FY25-26 was ₹21.85 crore, with a stated minimum target of ₹100 crore for FY26-27. On the cost side, materials accounted for 5.6% of revenue, employees 1.1%, other operating expenses 3.5%, depreciation 0.5%, and capex 9.8%.
Measured from the filed financials, judged against its Specialty Chemicals peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from SUDARSHAN PHARMA INDUSTRIES LI's filed financials and exchange disclosures
SUDARSHAN PHARMA INDUSTRIES LI is a Chemicals & Petrochemicals company listed on BSE.
Yes. Over the trailing twelve months SUDARSHAN PHARMA INDUSTRIES LI reported a net profit of ₹28 Cr on revenue of ₹871 Cr.
Not in the latest reported year — SUDARSHAN PHARMA INDUSTRIES LI's dividend payout for FY26 was nil.
No. Debt stands at 1.81× equity, and it carries net debt of ₹282 Cr. That is lower than 4% of its 101 Specialty Chemicals peers.
On trailing P/E, SUDARSHAN PHARMA INDUSTRIES LI ranks 70 of 103 in Specialty Chemicals — cheaper than 32% of them, against an industry median of 23.4×. This is a position, not a valuation judgement.
On a typical session SUDARSHAN PHARMA INDUSTRIES LI moves 1.99% — that is the median absolute close-to-close move across its last 268 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by SUDARSHAN PHARMA INDUSTRIES LI appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
